SYNAPTIC PHARMACEUTICAL CORP
10-Q, EX-27, 2000-11-03
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: SYNAPTIC PHARMACEUTICAL CORP, 10-Q, 2000-11-03
Next: ASTROPOWER INC, 10-Q, 2000-11-03



<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                       1,930,000
<SECURITIES>                                29,949,000
<RECEIVABLES>                                2,500,000
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            18,501,000
<PP&E>                                      11,837,000
<DEPRECIATION>                               6,876,000
<TOTAL-ASSETS>                              40,690,000
<CURRENT-LIABILITIES>                        1,991,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                       108,000
<OTHER-SE>                                  38,102,000
<TOTAL-LIABILITY-AND-EQUITY>                40,690,000
<SALES>                                              0
<TOTAL-REVENUES>                             3,471,000
<CGS>                                                0
<TOTAL-COSTS>                               14,823,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (9,796,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (9,796,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (9,796,000)
<EPS-BASIC>                                     (0.90)
<EPS-DILUTED>                                   (0.90)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission